Ditchcarbon
  • Contact
  1. Organizations
  2. Taiyen Biotech
Public Profile
Medical Device Manufacturing
TW
updated a month ago

Taiyen Biotech Sustainability Profile

Company website

Taiyen Biotech Co., Ltd., commonly referred to as Taiyen Biotech, is a leading player in the biotechnology industry, headquartered in Taiwan (TW). Established in 2000, the company has made significant strides in the development of innovative health products, focusing on dietary supplements and functional foods that cater to a growing health-conscious market. With a strong presence in Asia and expanding operations globally, Taiyen Biotech is renowned for its unique formulations that combine traditional wisdom with modern science. Their core offerings include probiotics, herbal extracts, and nutritional supplements, all designed to enhance well-being and support a healthy lifestyle. Recognised for its commitment to quality and research, Taiyen Biotech has achieved notable milestones, positioning itself as a trusted name in the health and wellness sector. The company continues to lead with cutting-edge solutions that meet the evolving needs of consumers worldwide.

DitchCarbon Score

How does Taiyen Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

22

Industry Average

Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Taiyen Biotech's score of 22 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.

23%

Let us know if this data was useful to you

Taiyen Biotech's reported carbon emissions

In 2023, Taiyen Biotech, headquartered in Taiwan (TW), reported a GHG emission intensity of approximately 1,762.46 kg CO2e per tonne from its Cosmetics Factory and about 50.17 kg CO2e per tonne from its Cigu Salt Plant. This data reflects the company's ongoing commitment to monitoring and managing its carbon footprint, although specific total emissions figures for Scope 1, 2, and 3 are not disclosed. For the year 2022, the company achieved a GHG emission intensity of around 1,198.79 kg CO2e per tonne for the Cosmetics Factory and approximately 32.23 kg CO2e per tonne for the Cigu Salt Plant. In 2021, these figures were about 2,111.54 kg CO2e per tonne and 28.15 kg CO2e per tonne, respectively. This indicates a significant improvement in emission intensity over the years, particularly in the Cosmetics Factory. Taiyen Biotech has set a near-term reduction target for 2023, aiming for a 1% reduction in Scope 2 emissions, which pertain to indirect emissions from energy use, using 2022 as the base year. This target is part of a broader strategy to enhance sustainability across its operations. Overall, while specific total emissions data is not available, Taiyen Biotech's commitment to reducing its carbon emissions and improving its environmental performance is evident through its established reduction targets and ongoing monitoring of emission intensities.

How Carbon Intensive is Taiyen Biotech's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Taiyen Biotech's primary industry is Medical Device Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Taiyen Biotech's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Taiyen Biotech is in TW, which we do not have grid emissions data for.

Taiyen Biotech's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Taiyen Biotech has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Taiyen Biotech's Emissions with Industry Peers

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251107.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy